U.S. FDA approves AbbVie's migraine prevention drug
Reuters
Published Sep 28, 2021 07:24PM ET
(Reuters) -AbbVie Inc said on Tuesday the U.S. health regulator approved its once-daily oral medicine for preventive treatment of migraine in adults, adding a third drug to the drugmaker's arsenal of therapies for severe headaches.
The drug, Qulipta, which AbbVie (NYSE:ABBV) will launch in early October, will enter a crowded market for migraine prevention drugs such as Eli Lilly (NYSE:LLY)'s Emgality, Amgen Inc (NASDAQ:AMGN)'s Aimovig and Biohaven Pharmaceutical Holding Co (NYSE:BHVN) Ltd's Nurtec ODT.
Analysts expect the drug to bring in sales of over $640 million by 2025, according to Refinitiv data.
AbbVie acquired Qulipta in 2020 as part of its $63 billion deal for Allergan (NYSE:AGN), along with anti-wrinkle and chronic migraine treatment Botox and acute migraine drug Ubrelvy.
Qulipta belongs to a class of drugs called calcitonin gene-related peptide (CGRP) receptor antagonists, also called "gepants", which act by blocking a pathway that seemingly plays a role in migraine activation.
The Food and Drug Administration's approval of Qulipta is supported by data from a late-stage study, which showed the drug caused a statistically significant reduction in average monthly headache days in patients compared to placebo.
Migraine, characterized by severe headache and other symptoms such as light sensitivity and nausea, affects about 39 million people in the United States, AbbVie said.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.